DSP Midcap Regular Plan-Growth
The fund is rated 0 stars. The balance between returns and downside risk provided limited support. Investment selection within each asset type and investment selection within each industry were the main limitations and did not provide enough support for a higher rating. Higher annual fee of 1.74% and above-average fund size of Rs 21,018.54 crore were minor drawbacks.
This fund has a bad track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 21018.538 AUM and a 1.74 expense ratio. Considering all these factors, we have rated this fund as 0.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 8 Oct 2026
Risk ratios
As of 30 Sep 2026
Portfolio
As of 31 Aug 2026
Market-cap split
Sector allocation
Holdings (65)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Coforge Ltd. | 4.48% | ₹940.77 Cr | 47,38,659 |
| Multi Commodity Exchange Of India Ltd. | 3.16% | ₹663.86 Cr | 19,52,533 |
| Fortis Healthcare Ltd. | 2.79% | ₹586.58 Cr | 64,68,009 |
| Ipca Laboratories Ltd. | 2.70% | ₹567.85 Cr | 28,75,353 |
| The Federal Bank Ltd. | 2.66% | ₹559.71 Cr | 1,56,91,347 |
| Max Financial Services Ltd. | 2.63% | ₹553.1 Cr | 35,15,987 |
| Cholamandalam Investment and Finance Company Ltd. | 2.59% | ₹544.31 Cr | 29,30,518 |
| The Phoenix Mills Ltd. | 2.48% | ₹522.29 Cr | 27,48,916 |
| Bharat Forge Ltd. | 2.42% | ₹507.93 Cr | 24,13,073 |
| Coromandel International Ltd. | 2.31% | ₹484.53 Cr | 25,42,249 |
Fund details
Long-term capital growth. Investment in equity and equity-related instruments predominantly of midcap companies/entities.
The scheme seek to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of midcap companies/entities.
Exit load of 1% if redeemed less than 12 months